These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 29369080)

  • 1. Coagulation assays in a case of apixaban overdose.
    Guadarrama DS; DeMarinis SM; Sweeney JD
    Blood Coagul Fibrinolysis; 2018 Mar; 29(2):231-235. PubMed ID: 29369080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Observational Study of the Factor Xa Inhibitors Rivaroxaban and Apixaban as Reported to Eight Poison Centers.
    Spiller HA; Mowry JB; Aleguas A; Griffith JR; Goetz R; Ryan ML; Bangh S; Klein-Schwartz W; Schaeffer S; Casavant MJ
    Ann Emerg Med; 2016 Feb; 67(2):189-95. PubMed ID: 26298448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme.
    Van Blerk M; Bailleul E; Chatelain B; Demulder A; Devreese K; Douxfils J; Jacquemin M; Jochmans K; Mullier F; Wijns W; China B; Vernelen K; Soumali MR
    Int J Lab Hematol; 2017 Aug; 39(4):402-408. PubMed ID: 28304137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of apixaban anti-factor Xa assay and impact of body weight.
    Wasan SM; Feland N; Grant R; Aston CE
    Thromb Res; 2019 Oct; 182():51-55. PubMed ID: 31450008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apixaban Auto-intoxication: Toxicokinetics and Coagulation Tests.
    Mast L; Verheul RJ; Reijnen R; van Rossen RCJM; Overdiek JWPM; Wilms EB
    Thromb Haemost; 2017 Nov; 117(11):2209-2211. PubMed ID: 28981556
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
    Beyer J; Trujillo T; Fisher S; Ko A; Lind SE; Kiser TH
    Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide.
    Douxfils J; Chatelain C; Chatelain B; Dogné JM; Mullier F
    Thromb Haemost; 2013 Aug; 110(2):283-94. PubMed ID: 23765180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
    Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V
    Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
    Barrett YC; Wang Z; Frost C; Shenker A
    Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of thromboprophylactic doses of apixaban and rivaroxaban on coagulation and thrombin generation in association with total hip replacement.
    Helin TA; Virtanen L; Manninen M; Leskinen J; Leppilahti J; Joutsi-Korhonen L; Lassila R
    J Thromb Thrombolysis; 2017 May; 43(4):562-569. PubMed ID: 28315166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
    Bonar R; Favaloro EJ; Mohammed S; Ahuja M; Pasalic L; Sioufi J; Marsden K
    Pathology; 2016 Jan; 48(1):60-71. PubMed ID: 27020211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.
    Gouin-Thibault I; Flaujac C; Delavenne X; Quenet S; Horellou MH; Laporte S; Siguret V; Lecompte T
    Thromb Haemost; 2014 Feb; 111(2):240-8. PubMed ID: 24172843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Xa activity in apixaban overdose: a case report.
    Barton J; Wong A; Graudins A
    Clin Toxicol (Phila); 2016 Nov; 54(9):871-873. PubMed ID: 27436437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of global laboratory methods and establishing on-therapy ranges for monitoring apixaban and rivaroxaban: Experience at a single institution.
    Park SH; Seo YH; Park PW; Kim KH; Seo JY; Lee HT; Kwoun WJ; Ahn JY
    J Clin Lab Anal; 2019 Jun; 33(5):e22869. PubMed ID: 30860622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.
    Song Y; Wang Z; Perlstein I; Wang J; LaCreta F; Frost RJA; Frost C
    J Thromb Haemost; 2017 Nov; 15(11):2125-2137. PubMed ID: 28846831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor.
    Becker RC; Yang H; Barrett Y; Mohan P; Wang J; Wallentin L; Alexander JH
    J Thromb Thrombolysis; 2011 Aug; 32(2):183-7. PubMed ID: 21516308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different Coagulation Indicators in Predicting Clinical Outcomes for Patients With Direct Oral Anticoagulants: A Systematic Review and Meta-analysis.
    Liu Z; Zhang H; Xie Q; Mu G; Zhou S; Wang Z; Wang Z; Jiang J; Xiang Q; Cui Y
    Clin Ther; 2020 Oct; 42(10):2066-2081.e9. PubMed ID: 32900534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International Normalized Ratio Is Significantly Elevated With Rivaroxaban and Apixaban Drug Therapies: A Retrospective Study.
    Ofek F; Bar Chaim S; Kronenfeld N; Ziv-Baran T; Berkovitch M
    Clin Ther; 2017 May; 39(5):1003-1010. PubMed ID: 28476405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry.
    Adelmann D; Wiegele M; Wohlgemuth RK; Koch S; Frantal S; Quehenberger P; Scharbert G; Kozek-Langenecker S; Schaden E
    Thromb Res; 2014 Oct; 134(4):918-23. PubMed ID: 25179518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lupus anticoagulant diagnosis in patients receiving direct oral FXa inhibitors at trough levels: A real-life study.
    Gay J; Duchemin J; Imarazene M; Fontenay M; Jourdi G
    Int J Lab Hematol; 2019 Dec; 41(6):738-744. PubMed ID: 31487115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.